Figure 5
AZD3463 inhibits tumor growth in different orthotopic NB xenograft mouse models.
(A) Photos of SH-SY5Y xenografted tumors and the corresponding kidney controls from DMSO control group and AZD3463 treatment group (15 mg/kg) were taken at the end of treatment (21 days). (B) SH-SY5Y derived tumor weights from control (N = 3) and treatment groups (N = 3) were presented as the mean with SDs. P < 0.01 (**) (Student’s t-test, two-tailed) was indicated. (C) Photos of NGP xenografted tumors and the corresponding kidney controls from DMSO control group and AZD3463 treatment group (15 mg/kg) were taken at the end of treatment (21 days). (D) NGP-derived tumor weights from control (N = 3) and treatment groups (N = 3) were presented as the mean with SDs. P < 0.05 (*) (Student’s t-test, two-tailed) was indicated. (E) The mice bearing SH-SY5Y and NGP xenograft tumors for 4 weeks were treated with DMSO or 15mg/kg of AZD3463 by intraperitoneal injection twice in 48 hrs and then the tumors were harvested and subjected to SDS-PAGE and immunoblotted with indicated antibodies. β-Actin was detected as a loading control.
